HUTCHMED
corporate_fare Company Profile
HUTCHMED (NASDAQ:HCM) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 25 items for HCM at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-26, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for HCM spans 6-K.
Recent high-impact activity:
- HUTCHMED Details SAFFRON and SANOVO Phase III Wins at ESMO, SAFFRON Published in NEJM
- HUTCHMED: AstraZeneca Submits US NDA for ORPATHYS + TAGRISSO in MET-Driven EGFR-Mutant Lung Cancer
- HUTCHMED Doses First Patient in Global Phase I Trial of HMPL-A830 KRAS-EGFR ATTC
- HUTCHMED Licenses KRAS-EGFR ATTC to GSK in Deal Worth Up to $1.3B
- SANOVO Trial: ORPATHYS plus TAGRISSO Improves PFS in First-Line EGFR-Mutant Lung Cancer
Financial Snapshot
Short Interest & Short Volume
4.73 days to coverFINRA reported short interest of 265,001 shares in HCM as of the October 15, 2026 settlement, a 3.9% decrease from the prior period — about 4.7 days to cover at its recent average daily volume. On October 30, 2026, 27.4% of HCM volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Insider Transactions
HCM files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.